Accelerating medicines partnership: Alzheimer's disease (AMP-AD) knowledge portal aids Alzheimer's drug discovery through open data sharing
RJ Hodes, N Buckholtz - Expert opinion on therapeutic targets, 2016 - Taylor & Francis
RJ Hodes, N Buckholtz
Expert opinion on therapeutic targets, 2016•Taylor & FrancisThe development and testing of new medications takes too long, costs too much, and fails
too often. This truism was the impetus for discussions in 2011 between Dr Francis Collins,
Director of the National Institutes of Health (NIH), and heads of a number of pharmaceutical
companies that eventually led in 2014 to the launch of a new public-private partnership to
address these problems, the Accelerating Medicines Partnership (AMP).[1] AMP includes
academic, industry, government (NIH, US Food and Drug Administration [FDA]), and …
too often. This truism was the impetus for discussions in 2011 between Dr Francis Collins,
Director of the National Institutes of Health (NIH), and heads of a number of pharmaceutical
companies that eventually led in 2014 to the launch of a new public-private partnership to
address these problems, the Accelerating Medicines Partnership (AMP).[1] AMP includes
academic, industry, government (NIH, US Food and Drug Administration [FDA]), and …
The development and testing of new medications takes too long, costs too much, and fails too often. This truism was the impetus for discussions in 2011 between Dr Francis Collins, Director of the National Institutes of Health (NIH), and heads of a number of pharmaceutical companies that eventually led in 2014 to the launch of a new public-private partnership to address these problems, the Accelerating Medicines Partnership (AMP).[1] AMP includes academic, industry, government (NIH, US Food and Drug Administration [FDA]), and nonprofit partners and focuses on three areas of disease: AlzheimerLs disease (AD), Type II diabetes, and rheumatoid arthritis/lupus erythematosus. The AMP effort is coordinated and managed through the Foundation for the NIH. Within the AD program, called AMP-AD, there are two projects: Biomarkers Project and Target Discovery and Preclinical Validation Project.
Taylor & Francis Online